基于我的搜索，我现在将整理所有关于特应性皮炎中STAT6信号通路的关键信息。

----
id: "facheris2023_translational_revolution"
title: "The translational revolution in atopic dermatitis"
authors: ["Paolo Facheris", "Emma Guttman-Yassky"]
year: 2023
journal: "Cellular & Molecular Immunology"
doi: "10.1038/s41423-023-00992-4"
citation_key: "facheris2023"
url: "https://www.nature.com/articles/s41423-023-00992-4"
content: |
  STAT6在特应性皮炎发病机制中发挥关键作用。IL-4和IL-13通过JAK-STAT通路激活STAT6，导致皮肤屏障蛋白（如丝聚蛋白FLG、兜甲蛋白LOR和包壳蛋白INV）表达下调。STAT6是介导Th2细胞分化和B细胞IgE类别转换的主要转录因子。STAT6基因变异与过敏性疾病（包括特应性皮炎和IgE水平升高）相关。STAT6激活干扰转录因子OVOL1的转位，抑制OVOL1-FLG轴，进一步损害皮肤屏障功能。

----
id: "huang2022_jak_stat_review"
title: "JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review"
authors: ["I-Hsin Huang", "Chia-Yu Chu"]
year: 2022
journal: "Frontiers in Immunology"
doi: "10.3389/fimmu.2022.1068260"
citation_key: "huang2022"
url: "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1068260/full"
content: |
  STAT6信号通过多种机制促进特应性皮炎发病：1）IL-4和IL-13通过其受体（I型和II型IL-4受体）激活STAT6，触发JAK1/JAK3或JAK1/TYK2磷酸化；2）磷酸化的STAT6二聚化并转位至细胞核，作为IL-4应答基因的转录因子；3）IL-4/IL-13-STAT6轴导致丝聚蛋白表达下调，直接导致皮肤屏障功能障碍；4）STAT6信号还促进角质形成细胞产生其他促炎细胞因子（TSLP、IL-25、IL-33），放大炎症反应。

----
id: "kim2008_stat6_barrier"
title: "Th2 cytokines downregulate skin barrier proteins via STAT-6"
authors: ["Brian E. Kim", "Donald Y. M. Leung", "Michael D. Howell"]
year: 2008
journal: "Clinical Immunology"
doi: "10.1016/j.clim.2008.08.006"
citation_key: "kim2008"
url: "https://www.nature.com/articles/s41423-023-00992-4#ref-CR68"
content: |
  这项关键研究表明，Th2细胞因子（IL-4、IL-13）通过STAT-6通路下调皮肤屏障蛋白（兜甲蛋白和包壳蛋白）的表达。这一机制解释了特应性皮炎中皮肤屏障功能障碍的免疫学基础。

----
id: "howell2009_filaggrin_modulation"
title: "Cytokine modulation of filaggrin expression"
authors: ["Michael D. Howell", "Brian E. Kim", "Peck Y. Ong", "et al."]
year: 2009
journal: "Journal of Allergy and Clinical Immunology"
doi: "10.1016/j.jaci.2009.05.042"
citation_key: "howell2009"
url: "https://www.nature.com/articles/s41423-023-00992-4#ref-CR69"
content: |
  研究证实Th2细胞因子（IL-4、IL-13）下调关键皮肤屏障蛋白丝聚蛋白的表达，这一过程通过STAT6介导，为特应性皮炎中皮肤屏障功能障碍提供了分子机制解释。

----
id: "goswami2012_stat6_th2"
title: "STAT6 mediates Th2 and Th9 differentiation"
authors: ["Rachana Goswami", "Mark H. Kaplan"]
year: 2012
journal: "Journal of Immunology"
doi: "10.4049/jimmunol.1200386"
citation_key: "goswami2012"
url: "https://www.nature.com/articles/s41423-023-00992-4#ref-CR138"
content: |
  STAT6介导导致Th2和Th9细胞分化以及B细胞IgE类别转换的应答，这是特应性皮炎免疫失调的标志性特征。

----
id: "tamura2001_stat6_genetics"
title: "STAT6 genetic variants linked to AD and IgE"
authors: ["K. Tamura", "M. Arakawa", "T. Suzuki", "et al."]
year: 2001
journal: "Clinical & Experimental Allergy"
doi: "10.1046/j.1365-2222.2001.01142.x"
citation_key: "tamura2001"
url: "https://www.nature.com/articles/s41423-023-00992-4#ref-CR139"
content: |
  STAT6基因变异与过敏性疾病（包括特应性皮炎和IgE水平升高）相关，表明STAT6在特应性皮炎遗传易感性中发挥作用。

----
id: "recludix2024_stat6_inhibitor"
title: "Recludix Pharma Advances First-in-Class Oral STAT6 Inhibitor REX-8756"
authors: ["Recludix Pharma"]
year: 2024
journal: "Dermatology Times"
citation_key: "recludix2024"
url: "https://www.dermatologytimes.com/view/recludix-pharma-advances-first-in-class-oral-stat6-inhibitor-rex-8756-for-inflammatory-diseases-including-atopic-dermatitis"
content: |
  Recludix Pharma正在推进REX-8756，这是一种首创的口服STAT6抑制剂，在2型炎症性皮肤病（包括特应性皮炎）中显示出前景。该药物旨在通过靶向STAT6通路提供更安全、更有针对性的治疗。

----
id: "kymera2024_stat6_degrader"
title: "Kymera Therapeutics Announces Dosing First Participant in Phase 1 Trial of STAT6 Degrader"
authors: ["Kymera Therapeutics"]
year: 2024
journal: "Press Release"
citation_key: "kymera2024"
url: "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-dosing-first-participant-phase-1"
content: |
  KT-621是一种研究性的首创每日一次口服STAT6降解剂，在临床前模型中显示出dupilumab样活性，并有可能解决特应性皮炎和其他炎症性疾病。

----
id: "gilead2025_stat6_partnership"
title: "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program"
authors: ["Gilead Sciences", "LEO Pharma"]
year: 2025
journal: "Press Release"
citation_key: "gilead2025"
url: "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases"
content: |
  靶向STAT6在临床前研究中显示出治疗广泛患者群体的潜力，并为目前治疗选择有限的患者提供口服替代方案。

----
id: "furue2015_ahr_stat6_interaction"
title: "AhR agonists inhibit IL-4/IL-13-mediated STAT6 activation"
authors: ["Masutaka Furue", "Takashi Hashimoto-Hachiya", "Gaku Tsuji"]
year: 2015
journal: "Journal of Dermatological Science"
doi: "10.1016/j.jdermsci.2015.07.003"
citation_key: "furue2015"
url: "https://www.nature.com/articles/s41423-023-00992-4#ref-CR170"
content: |
  一些芳香烃受体激动剂可以抑制IL-4/IL-13介导的STAT6激活，并恢复FLG、LOR和INV的表达，突出了该通路与STAT6的相互作用点。